127 related articles for article (PubMed ID: 37293737)
1. Unfavorable early-stage Hodgkin lymphoma: assessment of patient characteristics in a real-world setting.
Gautam S; Yeola S; Nahar A; Sarpong EM; Prescott J; Yang X; Sineshaw HM
Future Oncol; 2023 Jun; 19(18):1249-1259. PubMed ID: 37293737
[TBL] [Abstract][Full Text] [Related]
2. Ten-year survival outcomes for patients with early stage classical Hodgkin lymphoma: An analysis from Kentucky Cancer Registry.
Myint ZW; Shrestha R; Siddiqui S; Slone S; Huang B; Ramlal R; Monohan GP; Hildebrandt GC; Saeed H
Hematol Oncol Stem Cell Ther; 2020 Mar; 13(1):17-22. PubMed ID: 31629724
[TBL] [Abstract][Full Text] [Related]
3. Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT study.
Evens AM; Yu KS; Liu N; Surinach A; Holmes K; Flores C; Fanale MA; Flora DR; Parsons SK
Future Oncol; 2024 Apr; 20(12):749-760. PubMed ID: 37665273
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
Bröckelmann PJ; Goergen H; Keller U; Meissner J; Ordemann R; Halbsguth TV; Sasse S; Sökler M; Kerkhoff A; Mathas S; Hüttmann A; Bormann M; Zimmermann A; Mettler J; Fuchs M; von Tresckow B; Baues C; Rosenwald A; Klapper W; Kobe C; Borchmann P; Engert A
JAMA Oncol; 2020 Jun; 6(6):872-880. PubMed ID: 32352505
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
6. Classical Hodgkin lymphoma, lymphocyte depleted type: clinicopathological analysis and prognostic comparison with other types of classical Hodgkin lymphoma.
Karube K; Niino D; Kimura Y; Ohshima K
Pathol Res Pract; 2013 Apr; 209(4):201-7. PubMed ID: 23478005
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and prognostic factors of primary extranodal classical Hodgkin lymphoma: a retrospective study.
Yang M; Ping L; Liu W; Xie Y; Aliya ; Liu Y; Nuersulitan R; Zhu J; Wu M; Song Y
Hematology; 2019 Dec; 24(1):413-419. PubMed ID: 30922173
[TBL] [Abstract][Full Text] [Related]
8. Real-World Outcomes of Hodgkin Lymphoma: A Multi-Centric Registry From India.
Bhurani D; Nair R; Rajappa S; Rao SA; Sridharan N; Boya RR; Raman GS; Menon H; Seshachalam A; Nimmagadda R
Front Oncol; 2021; 11():799948. PubMed ID: 35223455
[TBL] [Abstract][Full Text] [Related]
9. Classical Hodgkin Lymphoma: Clinicopathologic Features, Prognostic Factors, and Outcomes From a 28-Year Single Institutional Experience.
Rose A; Grajales-Cruz A; Lim A; Todd A; Bello C; Shah B; Chavez J; Pinilla-Ibartz J; Saeed H; Sandoval-Sus J; Isenalumhe L; Sokol L
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):132-138. PubMed ID: 32950461
[TBL] [Abstract][Full Text] [Related]
10. Incidence and Risk Factors of Infections Among Diffuse Large B-cell Lymphoma and Classical Hodgkin's Lymphoma Patients in a Tertiary Care Center in Saudi Arabia: A Retrospective Cohort Study.
Alelyani RH; Alghamdi AH; Almughamisi TA; Alshareef AM; Kadasa AN; Alrajhi AM; Alburayk AK; Barefah AS; Radhwi OO; Almohammadi AT; Bahashawan SM; AlAhwal HM
Cureus; 2023 Mar; 15(3):e35922. PubMed ID: 36911585
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and treatment results of pediatric Hodgkin's lymphoma: A single center experience.
Büyükkapu-Bay S; Çorapçıoğlu F; Aksu G; Anık Y; Demir H; Erçin C
Turk J Pediatr; 2015; 57(4):359-66. PubMed ID: 27186698
[TBL] [Abstract][Full Text] [Related]
12. Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience.
Advani RH; Hoppe RT; Maeda LS; Baer DM; Mason J; Rosenberg SA; Horning SJ
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1374-9. PubMed ID: 20934280
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
Nogová L; Reineke T; Brillant C; Sieniawski M; Rüdiger T; Josting A; Bredenfeld H; Skripnitchenko R; Müller RP; Müller-Hermelink HK; Diehl V; Engert A;
J Clin Oncol; 2008 Jan; 26(3):434-9. PubMed ID: 18086799
[TBL] [Abstract][Full Text] [Related]
15. A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome.
Chohan KL; Young JR; Lester S; Alhaj Moustafa M; Rosenthal A; Tun HW; Hoppe BS; Johnston PB; Micallef IN; Habermann TM; Ansell SM
Blood Adv; 2022 Jul; 6(14):4241-4250. PubMed ID: 35617689
[TBL] [Abstract][Full Text] [Related]
16. Advanced Stage Hodgkin Lymphoma: Patient Management.
Gini G; Cimminiello M; Galieni P; Hohaus S; Nassi L; Picardi M; Romano A; Tarantini G
Acta Biomed; 2020 May; 91(S-5):5-12. PubMed ID: 32525129
[TBL] [Abstract][Full Text] [Related]
17. Survival among patients with composite and sequential lymphoma between primary mediastinal lymphoma/diffuse large B-cell lymphoma and classical Hodgkin lymphoma: A population-based study.
Tao Y; Chen H; Liu D; Dai X
Leuk Res; 2021 Dec; 111():106669. PubMed ID: 34333276
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Roemer MG; Advani RH; Ligon AH; Natkunam Y; Redd RA; Homer H; Connelly CF; Sun HH; Daadi SE; Freeman GJ; Armand P; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Rodig SJ; Shipp MA
J Clin Oncol; 2016 Aug; 34(23):2690-7. PubMed ID: 27069084
[TBL] [Abstract][Full Text] [Related]
19. The role of IgG4-positive plasma cell population in classic Hodgkin lymphoma.
Guler B; Tekden BC; Cetin G; Yildiz P; Turna S; Uysal O; Sinal I
J Hematop; 2023 Dec; 16(4):191-197. PubMed ID: 38175429
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of red blood cell distribution width and platelet/lymphocyte ratio in early-stage classical Hodgkin lymphoma.
Tao Y; Zhou Y; Chen H; Qin Y; He X; Liu P; Zhou S; Yang J; Zhou L; Zhang C; Yang S; Gui L; Shi Y
Future Oncol; 2022 May; 18(15):1817-1827. PubMed ID: 35179068
[No Abstract] [Full Text] [Related]
[Next] [New Search]
